Irinotecan (CPT-11) is a key drug for the treatment of various cancers. CPT-11 can be considered to be a prodrug, since it needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. However, CPT-11 may induce severe diarrhea and bone marrow suppression as adverse effects, thus leading to treatment interruption. The tumor-specific activation of CPT-11 is a possible strategy to avoid the severe toxicities by reducing the serum concentration of CPT-11. In this study, we constructed human liver carboxylesterase-2 fused with anticarcinoembryonic antigen (CEA) scFv as a targeting molecule. The recombinant enzyme anchors onto the tumor cell surface CEA, and thus metabolize CPT-11 extracellularly. In addition a secreted tumor-targeted form of carboxylesterase should help prevent the leakage of the enzyme from the site of the tumor into the circulation. This fusion protein showed CPT-11 activation to SN-38 and specific binding to CEA-expressing cells. In combination with CPT-11, the recombinant carboxylesterase protein exerted antiproliferative effects on human cancer cells. This recombinant enzyme is, therefore, a promising new tool in enzyme prodrug therapy for the treatment of carcinoma with CPT-11.
Introduction
A major limiting factor in cancer chemotherapy is its toxicity to normal tissues. 1 To circumvent this problem various tumor-targeting approaches have been developed. One of the most promising methods is antibody-directed enzyme prodrug therapy (ADEPT) in which tumorspecific antibody is used to target an effecter molecule to the tumor. 2, 3 In ADEPT, an antibody/enzyme conjugate is administered intravenously followed by the systemic administration of a nontoxic prodrug. The prodrug is then metabolized by the tumor-localized enzyme to generate a potent cytotoxic drug. One advantage of ADEPT is the high concentration of cytotoxic drugs only in tumors, thus minimizing the degree of systemic toxicity. The activated low-molecular weight drug diffuses throughout the tumor mass, killing not only antigen-expressing cells but also neighboring antigen-negative or antibody unbound tumor cells due to a bystander effect.
Camptothecin analog (CPT-11; irinotecan) has been shown to be activated by carboxylesterase (CE) enzymes from the rat and human to the potent DNA topoisomerase I inhibitor (SN-38). 4 The role of CPT-11 as single agent or in combined modality regimens has been investigated in a number of other cancers, including small and non-small cell lung cancer, gastric cancer, cervical cancer, malignant brain tumors, ovarian cancer and pancreatic cancer. [5] [6] [7] CPT-11 is considered to be a key anticancer drug in a wide variety of cancers, and its anticancer effect is attributed to the metabolite SN-38, which is from 100 to 1000 times more active than the parent compound. 8, 9 The majority of SN-38 is generated by CEs in the liver, intestine and blood after the intravenous administration of CPT-11. 10 Severe intestinal toxicity remains one of the still unresolved problems linked to irinotecan administration, thus resulting in its dose-limiting toxicity (DLT). Recent clinical trials have shown that CPT-11 causes grade 3 or 4 diarrhea in an NCI-CTC adverse effect grading system in at least 40% of patients, 11 thus leading to a premature interruption of chemotherapy. To avoid such severe CPT-11 related toxicity, a dose reduction of CPT-11 is needed, thereby resulting in a weakened anticancer effect.
CEA is expressed by a number of tumors of epithelial origin, most notably colorectal carcinoma, but not in normal adult tissue. 12 CEA has been also used for the cancer cell targeting of antineoplastic agents or radionuclides bound to tumor-selective anti-CEA monoclonal antibodies (mAbs). 13 Recently, a novel single chain antibody, F11-39, was reported to show a high affinity to CEA expressed on the tumor cell surface and it discriminates CEA in tumor tissues from the other CEA gene family antigens in normal tissue by Kuroki et al. 14 In this study we constructed a fusion protein consisting of a secreted form of human carboxylesterase (sCE2) as a catalytic domain and an F11-39 single chain antibody as a targeting domain. This fusion protein, F39-sCE2 anchors onto CEA and thus damages the CEA-expressing cells specifically in combination with CPT-11 in vitro and in vivo through the local production of SN38. This strategy may improve the anticancer effect of CPT-11 with a less toxic dose.
Materials and methods

Cell lines
The human gastric cancer cell line, NUGC3 and human cervical carcinoma cell line, HeLa were provided by Japanese Collection of Research Bioresources (JCRB). The cells were cultured in the media recommended by the provider and incubated at 37 1C with 5% CO 2 .
Construction of pF39-sCE2
The cDNAs of human anti-CEA scFv F39 and human carboxylesterase (CE2, GenBank accession number; BC032095) were a kind gift from Dr Masahide Kuroki (Fukuoka University, Japan) 15 and Dr Tomomichi Sone (Setsunan University, Japan), respectively. The cellular retention signal HTEL was deleted from CE2 cDNA by PCR, thereby creating a soluble from of CE2 (sCE2). Thereafter, F39 and sCE2 was bound by a flexible (Gly 4 Ser) 2 linker. PCR was performed with 30 cycles of denaturation (94 1C, 30 s), annealing (65 1C, 30 s), and extension (72 1C, 1.5 min). The sequences of the primers were as follows; CE2 sense primer: 5 0 -CAGGACTCAGC TAGCCCCATCCGGACCACA-3 0 , CE2 antisense primer: 5 0 -ACTAGTTCTCTCTTCAGGCTCCTCGAGCTC-3 0 . Finally, this fused cDNA was inserted into the eukaryotic expression vector, pSecTag2 (Invitrogen, Groningen, The Netherlands) thus creating pF39-sCE2. In this vector, the IgG kappa leader peptide was placed at the N-terminal of the inserted cDNA in order to direct the protein into the secretory pathway (Figure 1 ).
Carboxylesterase activity assay
The culture medium of HeLa cells transfected with pF39-sCE2 or pSectag2 were concentrated 10 times using Protein-Concentrate kit (Millipore, Billerica, MA). The concentrated medium was used as conditioned medium containing F39-sCE2 or negative control medium, respectively. The conditioned medium or negative control medium was then incubated with CPT-11 (10 mM) for 24 h. The serum-free culture medium of intact HeLa cells was also used in the same experiment to analyze the serum CE activity. The concentration of SN-38 in the medium was measured by the HPLC with a fully automated online solid-phase extraction system, PROSPEKT. 16 In vitro cytotoxicity assay HeLa or NUGC3 cells (2.5 Â 10
3 ) were plated in a 96-well microtiter plate. After 24 h, the culture medium was replaced with the conditioned medium containing F39-sCE2 or a negative control. Next, these cells were incubated for 6 h to allow F39-sCE2 to bind to CEA. Thereafter the medium was removed and rinsed vigorously, and replaced with a fresh culture medium containing 5%FCS with or without CPT-11 (1 mM). After an additional 72 h culture, viable cells were evaluated using the MTS assay (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay; Promega, Madison, WI). The MTS color development was quantified as an optical density at 490 nm by an ImmunoMini NJ-2300 Microplate Reader (InterMed, Tokyo, Japan).
To visualize the cytotoxic effect, crystal violet staining was also performed. Cells (1 Â 10 5 ) were plated in 24-well plates, and were treated in the same manner as described above. Finally, the cells in all wells were fixed and stained with 1% crystal violet in 70% ethanol for 45 min, followed by washing with tap water to remove any excess color. The plates were dried, and images of stained cells were captured with a Kodak DC260 digital camera (Eastman Kodak, Rochester, NY).
CEA expression of HeLa cells infected with AdCMV/ CEA HeLa cells were infected with AdCMV/CEA 17 at 10 MOI to overexpress CEA. After 72 h postinfection, cells were fixed using acetone/methanol (1:1). Immunocytochemistry was performed using a streptavidin-biotinylated peroxidase technique with a monoclonal antihuman-CEA antibody (COL1, Nichirei, Tokyo, Japan) and a Histofine SAB-PO kit (Nichirei, Tokyo, Japan). Figure 1 A schematic representation of the F39-sCE2 expression cassette. The structural elements of pF39-sCE2 include a strong cytomegalovirus promoter, the IgG kappa leader sequence, without a retention signal, is inserted as a fragment into pSectag2.
Tumor targeting carboxylesterase improve the anticancer effect by irinotecan J Uchino et al Cytotoxic effect of scFv-sCE2 to CEA-expressing cells in vivo To evaluate the cytotoxicity of scFv-sCE2 to CEAexpressing hepatocyte in vivo, nude mice (BALB/C-nu/nu, Charles River Laboratories Japan Inc., Osaka, Japan) were injected by 5 Â 10 8 pfu of AdCMV/CEA or AdCMV/Luc through tail vein. After 3 days, the conditioned medium containing scFv-sCE2 or negative control medium was administrated intravenously. CPT-11 (50 mg kg
À1
) was injected into mouse peritoneal space simultaneously. After 24 h, the mice were killed, and blood samples were obtained to measure the serum ALT concentration. The livers in the treated mice were resected and fixed in 10% buffered formalin overnight and processed into paraffin blocks. Sections (4 mm) were deparaffinized, and thereafter underwent immunohistochemical staining as described previously. 18 In vivo tumor suppressive effect by CPT-11 All animals were treated according to the protocols approved by the animal care committee of Kyushu University. The experiment was carried out under both the Guidelines for Animal Experiments of Kyushu University and the Law and Notification of the Japanese government. The tumor suppressive effect in vivo was analyzed as described previously. 19 Briefly, NUGC3 cells (1 Â 10 7 ) were injected into the subcutaneous space of the dorsal skin to make a tumor on the nude mouse. The tumor volume was calculated using the formula
)/2, a and b are the longest and shortest diameter, respectively. When tumor size reached 6 mm in diameter, conditioned medium containing scFv-sCE2 or control medium was injected into the tumor directly. CPT-11 (17 or 50 mg kg
) was also injected into mouse peritoneal space simultaneously. After the treatment, the tumor growth was observed for 28 days. Student's t-test was used to compare the tumor volumes, with a value of Po0.05 being considered to be significant.
Results
F39-sCE2 converted CPT-11 to SN-38
We first analyzed whether F39-sCE2 is capable of converting the CPT-11 into an active metabolite SN-38. As shown in Figure 2 , the mixture of the conditioned medium containing F39-sCE2 and CPT-11 produced a significant amount of SN38. The SN-38 concentration was higher than the level that was previously shown to have a cell killing effect. 20 Negative control medium also showed a certain level of SN-38 probably due to the CE activity of the bovine serum added to the culture medium since the serum-free culture medium did not show SN-38 producing activity at all.
CEA-dependent cytotoxicity augmentation by F39-sCE2 in vitro
To confirm the CEA-dependent augmentation of the cytotoxic effect of CPT-11 with F39-sCE2, we used the two cell lines, that is, NUGC3 as CEA positive cell and HeLa as CEA negative cell in this experiment. As shown in Figure 3 , the conditioned medium containing F39-sCE2 showed the suppression of NUGC3 cell proliferation with CPT-11. Since the conditioned medium was completely removed and the cells were rinsed vigorously before the addition of CPT-11, the growth suppressive effect was considered to depend on the F39-sCE2 bound The conditioned media suppressed the NUGC3 cell proliferation with CPT-11 significantly. While, the suppressive effect was weak in HeLa cells. The experiment was repeated three times independently, and the each activity was shown as the average with error bar.
Tumor targeting carboxylesterase improve the anticancer effect by irinotecan J Uchino et al on the cell surface. On the other hand, F39-sCE2 was found to have only a marginal effect on HeLa cells which may depend on nonspecific bound F39-sCE2. The difference in the proliferation suppressive effect in both cells is significant. These results were also confirmed by the crystal violet assay (data not shown).
CEA-dependent cytotoxicity augmentation by F39-sCE2 in vivo
We analyzed the CEA-dependent augmentation of the cytotoxic effect of CPT-11 with F39-sCE2 in vivo. Since the blood flow to subcutaneous tumor is limited, we targeted the liver as a vascular rich organ instead of the tumor tissue in this experiment. Using human CEA expressing adenovirus, we caused the mouse liver to overexpress CEA. As shown previously, adenovirus which was injected into a mouse via tail vein intravenously is mainly trapped in the mouse liver 21 and then the liver expresses the transferred gene product in hepatocytes. As shown in Figure 4 , we confirmed the CEA expression on the surface of hepatocyte immunohistochemically after the AdCMV/CEA injection. The stronger staining of the hepatocytes adjacent to the hepatic vein supports the adenovirus-mediated gene transfer via the blood stream. We next moved to the in vivo cytotoxicity assay using this CEA expressing mouse model. The cytotoxicity of conditioned media and CPT-11 was evaluated in the liver by the serum ALT concentration. As shown in Figure 5 , only an injection of the conditioned medium containing F39-sCE2 or AdCMV/CEA induced only minimal elevation of ALT. However, when injected by the combination of conditioned medium and AdCMV/CEA, marked elevation of ALT concentration was seen. These results showed F39-sCE2 bound to the hepatocyte surface CEA, thereby damaging the CEA expressing hepatocytes through the conversion of CPT-11 to SN-38 in vivo as well as in vitro.
Tumor growth suppression by F39-sCE2 in vivo We finally investigated whether F39-sCE2 in combination with CPT-11 could suppress a tumor growth in vivo. To this end, we established the subcutaneous tumors in nude mice, and then directly injected either conditioned medium containing F39-sCE2 or control medium into the tumor. Two doses of CPT-11, 50 mg or 17 mg kg À1 was injected in the peritoneal space simultaneously. CPT-11 (50 mg kg À1 ) is a sublethal dose as shown in our previous experiment. As shown in Figure 6 , the tumor injected with control medium increased in size exponentially even after the 50 mg kg À1 of CPT-11 injection. In contrast, 50 mg kg À1 of CPT-11 in combination with conditioned medium containing F39-sCE2 suppressed the tumor growth completely. When the CPT-11 dose decreased to one-third, that is, 17 mg kg
À1
, it was clear that the tumor suppressive effect in combination with conditioned medium was stronger than that with the negative control.
Discussion
ADEPT is an adaption of the immunotoxin concept, delivering an enzyme rather than a toxin to antigenic sites on tumor cells. The enzyme then catalytically metabolizes a separately given prodrug, releasing an effector able to diffuse to and enter surrounding tumor cells. 22, 23 The efficacy of this approach depends on a number of factors related to choice of antibody, enzyme and prodrug. Some particular requirements of the prodrug include the ability Figure 4 Carcinoembryonic antigen (CEA) expression in mouse hepatocytes in vivo. Nude mice were injected by 5 Â 10 8 pfu of (a) AdCMV/CEA or (b) AdCMV/Luc through the tail vein. Three days after injection, mouse livers were resected and thereafter underwent immunohistochemical staining. The hepatocyte in the mouse injected by AdCMV/CEA showed the positive staining. The stronger staining of the hepatocytes adjacent to the hepatic vein supports the adenovirus-mediated gene transfer via the blood stream. While, the mouse injected by the negative control virus did not show any staining.
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CPT-11 is a prodrug for the treatment of gastric, colon and lung cancer. One enzyme that converts CPT-11 into the toxic drug SN-38 is CE. By increasing the concentration of CE at the site of a tumor via the ADEPT approach, the conversion of CPT-11 to SN-38 will be enhanced at the site of the tumor, thus leading to tumorspecific cytotoxicity.
Recently, Wierdl et al. 24 described the construction of an adenoviral vector containing the cDNA encoding a secreted form of rabbit liver CE, which is probably the most efficient isoform of CE. 10 Because a nonhuman enzyme such as rabbit CE might elicit an immune response in humans and the repeated administration of Ad-sCE2 is anticipated in clinical applications, we preferred to express a secreted form of a human CE2 in our study. Human CE1 or CE3 showed a low conversion velocity and a low hydrolysis rate for CPT-11 in comparison with CE2. 25 In this study, we used the human liver CE2 enzyme to sensitize human tumor cells to CPT-11.
CEA is one of the most useful human tumor markers and it is usually localized on all sides of the cell membrane in multicellular arrays and directly faces blood flow or tissue fluid. As a result, tumor CEA is considered to be a useful target for immunotherapy or immunogene therapy using anti-CEA antibody. Kuroki et al.
14 have previously prepared a novel scFv, F11-39, which shows a high affinity to CEA and discriminates CEA in tumor tissues from the other CEA gene family antigens in normal tissues. In this study, we constructed, expressed and characterized a new fusion protein that consisted of sCE2 and an anti-CEA scFv antibody derived from F11-39.
The secreted fusion protein exhibited marked CE enzymatic activity. Using the HPLC analysis the fusion protein was shown to be able to efficiently convert CPT-11 into SN-38. Experiments with NUGC-3 gastric carcinoma cells that were incubated with fusion protein and a low concentration of CPT-11 also showed a complete growth inhibition of these cells.
We previously constructed a recombinant adenoviral vector encoding CEA cDNA driven by a CMV promoter to accomplish genetic induction of CEA expression as a target for fusion protein. 17 The efficacy of our AdCMV/ CEA vector construct in accomplishing transduction of target cells was evident by an immnocytochemical analysis with anti-CEA COL-1 Mab. Furthermore, we demonstrated a considerable expression of transgene in hepatocytes in vivo by a single injection of AdCMV/CEA through mouse tail vein. To confirm the efficacy of the chimeric protein, AdCMV/CEA was injected via tail vein and thereafter chimeric protein and CPT-11 were administered intravenously and intraperitoneally, respectively. Then 3 days later a blood sample was obtained to determine the ALT level. As a result, a significant hepatic dysfunction was observed in the group, which received the fusion protein, and we thus concluded the fusion protein to have the nature of a single chain antibody and enzymatic activity.
Oosternfoff et al. 26, 27 also reported the anticancer effect using a similar soluble form of CE fused with an anti-EpCAM scFv previously. In this experiment, we Figure 5 The cytotoxicity of scFv-CE2 to carcinoembryonic antigen (CEA) expressing hepatocyte in vivo. Nude mice were injected by AdCMV/CEA or AdCMV/Luc through the tail vein. After 3 days, conditioned media containing scFv-CE2 or control media were administrated intravenously. CPT-11 (50 mg kg
À1
) was injected into the mouse peritoneal space simultaneously. After 24 h, blood samples were then obtained to measure the serum ALT concentration. When injected by conditioned media and AdCMV/CEA together, a marked elevation of the ALT concentration was seen. N ¼ 3 in each group, and the average ALT with error bar was shown. Figure 6 Tumor growth curve in each group was shown. Mice were categorized into four groups according to the treatment method as follows; K treated with 17 mg kg À1 of CPT-11 and negative control medium, ' treated with 50 mg kg À1 of CPT-11 and negative control medium, J treated with 17 mg kg À1 of CPT-11 and conditioned medium containing pF39-CE2, & treated with 50 mg kg À1 of CPT-11 and conditioned medium containing pF39-CE2. N ¼ 6 in each group. The average tumor volume with standard error bar was shown in the tumor growth curve. The tumor size treated with conditioned medium was suppressed significantly compared with that treated with negative control medium.
Tumor targeting carboxylesterase improve the anticancer effect by irinotecan J Uchino et al targeted a CEA instead of EpCAM to anchor lung cancer cells more efficiently. Moreover, we confirmed the tumor growth suppression in vivo experiment although Oosternhoff et al. showed the anticancer effect only in the cancer cells with gene transduction in vitro experiment. Since the chimeric protein is able to target the cancer cells, it is not necessary that the protein be produced by cancer cell itself. We also confirmed that the chimeric protein damaged the CEA expressing hepatocyte through blood stream in vivo experiment. That shows the chimeric protein is applicable for intravenous administration that is useful in the view of clinical setting.
In the tumor suppression experiment, we injected the chimeric protein into the subcutaneous tumor directly to evaluate the suppressive effect. The growth of the tumor treated with F39-sCE2 was suppressed completely in combination with 50 mg kg À1 of CPT-11. While, the tumor in the negative control mice increased in size continuously with the same dose of CPT-11. Therefore, the chimeric protein enhanced the suppressive effect clearly. Although the SN-38 concentration in the tumor was not measured in this experiment, CPT-11 seems to be converted efficiently by the chimeric protein injected in the tumor. Moreover, chimeric protein suppressed the tumor significantly with a less dose of CPT-11. With the dose of 17 mg kg À1 CPT-11, significant anticancer effect is not shown although the adverse effect is minimal. Therefore, the chimeric protein is possible to reduce the normal organ damage keeping the anticancer effect.
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